MetrioPharm Press Releases
-
Single-dose part of MP1032’s first-in-man clinical trial successful
MetrioPharm AG announces results of the single-dose part of its Phase I first-in-man clinical trial with its lead compound MP1032.
-
MetrioPharm AG announces the start of phase 1 clinical trial with a novel macrophage modulator
Metriopharm announced today that the Phase I clinical trial of its lead compound MP1032 has now commenced with the dosing of the first group of subjects.
-
MetrioPharm announces regulatory approval to initiate clinical development of MP1032
MetrioPharm AG has received approval to commence its phase 1 clinical trial with MP1032 from the German regulatory authority (BfArM).
-
MetrioPharm AG: New Member of the Board
The Rt Hon David Davis, Member of Parliament and former British Junior Minister for Public Service and Science, has joined the Board of Directors of MetrioPharm AG.
-
MetrioPharm AG has submitted the phase I investigational new drug application for MP1032
MetrioPharm AG has submitted the phase I investigational new drug application for its lead compound MP1032 to BfArM (German Federal Institute for Drugs and Medical Devices).
-
MetrioPharm AG attracts high profile pharma executive
In November 2014, John J. Alam, M.D. joined MetrioPharm AG as Senior Medical Advisor and Non-Executive Board Member.
-
MetrioPharm AG: Phase I – the next step
Since MetrioPharm AG was able to finalize the regulatory pharmacology and toxicology studies in the past months, all requirements for clinical studies are now fulfilled.
-
MetrioPharm AG: 9th International Congress on Autoimmunity (Nice)
On March 26. – 30. 2014 over 2000 scientists from around the world met in Nice for the 9th International Congress on Autoimmunity.
-
MetrioPharm Milestones – on the route to a new drug
The most important outcome was MP1032's superior safety profile as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year.